The Law Offices of Frank R. Cruz continues its investigation on behalf of Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQ: TMCI) investors concerning the Company and its officers’ possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On May 7, 2024, Treace released its first quarter 2024 financial results and revised its full year 2024 guidance, lowering it by approximately $20 million, citing “increased use of MIS Osteotomy solutions and more competition from knockoffs of [the Company’s] Lapiplasty products.”

On this news, Treace’s stock price fell $6.95, or 62.5%, to close at $4.17 per share on May 8, 2024, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Treace securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250109575722/en/

The Law Offices of Frank R. Cruz Continues Its Investigation of Treace Medical Concepts, Inc. (TMCI) on Behalf of Investors